229 related articles for article (PubMed ID: 33169439)
21. A mechanism for the suppression of homologous recombination in G1 cells.
Orthwein A; Noordermeer SM; Wilson MD; Landry S; Enchev RI; Sherker A; Munro M; Pinder J; Salsman J; Dellaire G; Xia B; Peter M; Durocher D
Nature; 2015 Dec; 528(7582):422-6. PubMed ID: 26649820
[TBL] [Abstract][Full Text] [Related]
22. Molecular characteristics of
Seeber A; Zimmer K; Kocher F; Puccini A; Xiu J; Nabhan C; Elliott A; Goldberg RM; Grothey A; Shields AF; Battaglin F; El-Deiry WS; Philip PA; Marshall JL; Hall M; Korn WM; Lenz HJ; Wolf D; Feistritzer C; Spizzo G
ESMO Open; 2020 Nov; 5(6):e000942. PubMed ID: 33229504
[TBL] [Abstract][Full Text] [Related]
23. PALB2 self-interaction controls homologous recombination.
Buisson R; Masson JY
Nucleic Acids Res; 2012 Nov; 40(20):10312-23. PubMed ID: 22941656
[TBL] [Abstract][Full Text] [Related]
24. A Validated Functional Analysis of Partner and Localizer of BRCA2 Missense Variants for Use in Clinical Variant Interpretation.
Brnich SE; Arteaga EC; Wang Y; Tan X; Berg JS
J Mol Diagn; 2021 Jul; 23(7):847-864. PubMed ID: 33964450
[TBL] [Abstract][Full Text] [Related]
25. Compromised BRCA1-PALB2 interaction is associated with breast cancer risk.
Foo TK; Tischkowitz M; Simhadri S; Boshari T; Zayed N; Burke KA; Berman SH; Blecua P; Riaz N; Huo Y; Ding YC; Neuhausen SL; Weigelt B; Reis-Filho JS; Foulkes WD; Xia B
Oncogene; 2017 Jul; 36(29):4161-4170. PubMed ID: 28319063
[TBL] [Abstract][Full Text] [Related]
26. RAD52 inactivation is synthetically lethal with deficiencies in BRCA1 and PALB2 in addition to BRCA2 through RAD51-mediated homologous recombination.
Lok BH; Carley AC; Tchang B; Powell SN
Oncogene; 2013 Jul; 32(30):3552-8. PubMed ID: 22964643
[TBL] [Abstract][Full Text] [Related]
27. Germline mutations of PALB2 gene in a sequential series of Chinese patients with breast cancer.
Zhang K; Zhou J; Zhu X; Luo M; Xu C; Yu J; Deng M; Zheng S; Chen Y
Breast Cancer Res Treat; 2017 Dec; 166(3):865-873. PubMed ID: 28825143
[TBL] [Abstract][Full Text] [Related]
28. Antiparallel Coiled-Coil Interactions Mediate the Homodimerization of the DNA Damage-Repair Protein PALB2.
Song F; Li M; Liu G; Swapna GVT; Daigham NS; Xia B; Montelione GT; Bunting SF
Biochemistry; 2018 Nov; 57(47):6581-6591. PubMed ID: 30289697
[TBL] [Abstract][Full Text] [Related]
29. Mutation status of RAD51C, PALB2 and BRIP1 in 100 Japanese familial breast cancer cases without BRCA1 and BRCA2 mutations.
Sato K; Koyasu M; Nomura S; Sato Y; Kita M; Ashihara Y; Adachi Y; Ohno S; Iwase T; Kitagawa D; Nakashima E; Yoshida R; Miki Y; Arai M
Cancer Sci; 2017 Nov; 108(11):2287-2294. PubMed ID: 28796317
[TBL] [Abstract][Full Text] [Related]
30. Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer.
Kim H; Cho DY; Choi DH; Oh M; Shin I; Park W; Huh SJ; Nam SJ; Lee JE; Kim SW
Breast Cancer Res Treat; 2017 Jan; 161(1):95-102. PubMed ID: 27783279
[TBL] [Abstract][Full Text] [Related]
31. Frequency and molecular characteristics of PALB2-associated cancers in Russian patients.
Preobrazhenskaya EV; Shleykina AU; Gorustovich OA; Martianov AS; Bizin IV; Anisimova EI; Sokolova TN; Chuinyshena SA; Kuligina ES; Togo AV; Belyaev AM; Ivantsov AO; Sokolenko AP; Imyanitov EN
Int J Cancer; 2021 Jan; 148(1):203-210. PubMed ID: 32997802
[TBL] [Abstract][Full Text] [Related]
32. Analysis of PALB2 gene in BRCA1/BRCA2 negative Spanish hereditary breast/ovarian cancer families with pancreatic cancer cases.
Blanco A; de la Hoya M; Osorio A; Diez O; Miramar MD; Infante M; Martinez-Bouzas C; Torres A; Lasa A; Llort G; Brunet J; Graña B; Perez Segura P; Garcia MJ; Gutiérrez-Enríquez S; Carracedo Á; Tejada MI; Velasco EA; Calvo MT; Balmaña J; Benitez J; Caldés T; Vega A
PLoS One; 2013; 8(7):e67538. PubMed ID: 23935836
[TBL] [Abstract][Full Text] [Related]
33. PALB2: the hub of a network of tumor suppressors involved in DNA damage responses.
Park JY; Zhang F; Andreassen PR
Biochim Biophys Acta; 2014 Aug; 1846(1):263-75. PubMed ID: 24998779
[TBL] [Abstract][Full Text] [Related]
34. MDC1 and RNF8 function in a pathway that directs BRCA1-dependent localization of PALB2 required for homologous recombination.
Zhang F; Bick G; Park JY; Andreassen PR
J Cell Sci; 2012 Dec; 125(Pt 24):6049-57. PubMed ID: 23038782
[TBL] [Abstract][Full Text] [Related]
35. Exploring the link between MORF4L1 and risk of breast cancer.
Martrat G; Maxwell CM; Tominaga E; Porta-de-la-Riva M; Bonifaci N; Gómez-Baldó L; Bogliolo M; Lázaro C; Blanco I; Brunet J; Aguilar H; Fernández-Rodríguez J; Seal S; Renwick A; Rahman N; Kühl J; Neveling K; Schindler D; Ramírez MJ; Castellà M; Hernández G; ; Easton DF; Peock S; Cook M; Oliver CT; Frost D; Platte R; Evans DG; Lalloo F; Eeles R; Izatt L; Chu C; Davidson R; Ong KR; Cook J; Douglas F; Hodgson S; Brewer C; Morrison PJ; Porteous M; Peterlongo P; Manoukian S; Peissel B; Zaffaroni D; Roversi G; Barile M; Viel A; Pasini B; Ottini L; Putignano AL; Savarese A; Bernard L; Radice P; Healey S; Spurdle A; Chen X; Beesley J; ; Rookus MA; Verhoef S; Tilanus-Linthorst MA; Vreeswijk MP; Asperen CJ; Bodmer D; Ausems MG; van Os TA; Blok MJ; Meijers-Heijboer HE; Hogervorst FB; ; Goldgar DE; Buys S; John EM; Miron A; Southey M; Daly MB; ; ; Harbst K; Borg A; Rantala J; Barbany-Bustinza G; Ehrencrona H; Stenmark-Askmalm M; Kaufman B; Laitman Y; Milgrom R; Friedman E; Domchek SM; Nathanson KL; Rebbeck TR; Johannsson OT; Couch FJ; Wang X; Fredericksen Z; Cuadras D; Moreno V; Pientka FK; Depping R; Caldés T; Osorio A; Benítez J; Bueren J; Heikkinen T; Nevanlinna H; Hamann U; Torres D; Caligo MA; Godwin AK; Imyanitov EN; Janavicius R; ; Sinilnikova OM; Stoppa-Lyonnet D; Mazoyer S; Verny-Pierre C; Castera L; de Pauw A; Bignon YJ; Uhrhammer N; Peyrat JP; Vennin P; Ferrer SF; Collonge-Rame MA; Mortemousque I; McGuffog L; Chenevix-Trench G; Pereira-Smith OM; Antoniou AC; Cerón J; Tominaga K; Surrallés J; Pujana MA
Breast Cancer Res; 2011 Apr; 13(2):R40. PubMed ID: 21466675
[TBL] [Abstract][Full Text] [Related]
36. Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in
Reiss KA; Mick R; O'Hara MH; Teitelbaum U; Karasic TB; Schneider C; Cowden S; Southwell T; Romeo J; Izgur N; Hannan ZM; Tondon R; Nathanson K; Vonderheide RH; Wattenberg MM; Beatty G; Domchek SM
J Clin Oncol; 2021 Aug; 39(22):2497-2505. PubMed ID: 33970687
[TBL] [Abstract][Full Text] [Related]
37. Functional analysis of genetic variants in the high-risk breast cancer susceptibility gene PALB2.
Boonen RACM; Rodrigue A; Stoepker C; Wiegant WW; Vroling B; Sharma M; Rother MB; Celosse N; Vreeswijk MPG; Couch F; Simard J; Devilee P; Masson JY; van Attikum H
Nat Commun; 2019 Nov; 10(1):5296. PubMed ID: 31757951
[TBL] [Abstract][Full Text] [Related]
38. Germline PALB2 Variants and PARP Inhibitors in Endometrial Cancer.
Cilento MA; Poplawski NK; Paramasivam S; Thomas DM; Kichenadasse G
J Natl Compr Canc Netw; 2021 Nov; 19(11):1212-1217. PubMed ID: 34781271
[TBL] [Abstract][Full Text] [Related]
39. A germline
Zhong Y; Schubert J; Wu J; Xu F; Lin F; Cao K; Zelley K; Luo M; Foster JB; Cole KA; MacFarland SP; Resnick AC; Storm PB; Li MM
Cold Spring Harb Mol Case Stud; 2020 Aug; 6(4):. PubMed ID: 32554798
[No Abstract] [Full Text] [Related]
40. The canine RAD51 mutation leads to the attenuation of interaction with PALB2.
Uemura M; Ochiai K; Morimatsu M; Michishita M; Onozawa E; Azakami D; Uno Y; Yoshikawa Y; Sasaki T; Watanabe M; Omi T
Vet Comp Oncol; 2020 Jun; 18(2):247-255. PubMed ID: 31518051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
